The present clinical trial aims at improving the current treatment for high-risk prostate cancer, evaluating safety and feasibility of a new RT mixed-beam scheme including photons and carbon ions. Encouraging results are coming from carbon ion facilities worldwide on the treatment of different tumors including prostate cancers. Carbon ions combine physical properties allowing for high dose conformity and advantageous radiobiological characteristics. The proposed mixed beam treatment has the advantage to combine a photon high conformity standard of care IMRT phase with a hypofractionated carbon ion RT boost delivered in a short overall treatment time.

No abstract

A new technique for range verification in proton beam therapy has been developed. It is based on the detection of the prompt γ rays that are emitted naturally during the delivery of the treatment. A spectrometer comprising 16 LaBr3(Ce) detectors in a symmetrical configuration is employed to record the prompt γ rays emitted along the proton path. An algorithm has been developed that takes as inputs the LaBr3(Ce) detector signals and reconstructs the maximum γ-ray intensity peak position, in full 3 dimensions. For a spectrometer radius of 8 cm, which could accommodate a paediatric head and neck case, the prompt γ-ray origin can be determined from the width of the detected peak with a σ of 4.17 mm for a 180 MeV proton beam impinging a water phantom. For spectrometer radii of 15 and 25 cm to accommodate larger volumes this value increases to 5.65 and 6.36 mm. For a 8 cm radius, with a 5 and 10 mm undershoot, the σ is 4.31 and 5.47 mm. These uncertainties are comparable to the range uncertainties incorporated in treatment planning. This work represents the first step towards a new accurate, real-time, 3D range verification device for spot-scanning proton beam therapy.